About Hikma
Hikma is a company based in Amman (Jordan) founded in 1978. It operates as a Direct-to-Consumer (D2C) and Professional Services. The company has 9,500 employees as of December 31, 2024. Hikma has completed 6 acquisitions, including Custopharm, EIMC Pharmaceuticals and Medlac Pharma. Hikma offers products and services including Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection.
- Headquarter Amman, Jordan
- Employees 9500 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Hikma Pharmaceuticals Plc
-
Annual Revenue
$3.07 B (USD)5.81as on Dec 31, 2024
-
Net Profit
$352.01 M (USD)83.81as on Dec 31, 2024
-
EBITDA
$788.34 M (USD)14.68as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
9500
as on Dec 31, 2024
-
Investments & Acquisitions
Custopharm
& 5 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Hikma
Hikma is a publicly listed company on the LSE with ticker symbol HIK in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Hikma
Hikma offers a comprehensive portfolio of products and services, including Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection.
High-quality injectable medicines are produced for global markets.
Biosimilar products are developed for bone health treatment.
Pain management injection is offered in prefilled syringes.
People of Hikma
Unlock access to complete
Unlock access to complete
Software Development Team
56 people
Leadership Team
30 people
Operations Team
25 people
Product Management Team
19 people
Legal and Compliance
14 people
Human Resources and Administration
10 people
Sales and Marketing
7 people
Senior Team
6 people
Unlock access to complete
Funding Insights of Hikma
Detailed funding history for Hikma
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hikma
Hikma has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Custopharm, EIMC Pharmaceuticals and Medlac Pharma.
Investment portfolio details for Hikma
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Developer and manufacturer of pharmaceutical parental products
|
Locked | Locked | 2008 | Locked | |
|
Employee benefits administration and insurance products are provided.
|
Locked | Locked | 2005 | Locked | |
|
Manufacturer of oncology drugs
|
Locked | Locked | 2003 | Locked |
Complete acquisition details for Hikma
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Hikma
Detailed financials for Hikma
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Hikma Comparisons
Peer comparison for Hikma
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Hikma
Detailed competitors of Hikma
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Hikma
Complete news archive for Hikma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hikma
Hikma was founded in 1978.
Hikma is headquartered in Amman, Jordan.
Riad Mishlawi is the current CEO of Hikma.
As of Dec 31, 2024, the latest employee count at Hikma is 9,500.
Annual revenue of Hikma is $3.07B as on Dec 31, 2024.
Hikma Pharmaceuticals PLC is engaged in the development, manufacturing, and distribution of high-quality medicines across North America, MENA, and Europe. Operations are focused on generics, specialty pharmaceuticals, and injectables. Solutions are provided through strategic acquisitions, expanded manufacturing capabilities, and investment in research and development. The company is committed to sustainability and advancing health by ensuring access to medicines, maintaining product quality, and upholding ethical standards. Various therapeutic areas are addressed to improve patient outcomes worldwide.
Hikma offers Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection.
Yes, Hikma is publicly traded on LSE under the ticker symbol HIK.
Hikma has made 6 acquisitions, including Custopharm, EIMC Pharmaceuticals, and Medlac Pharma.
The ticker symbol of Hikma is HIK on LSE.